Continuum Pearls: Optimizing Management of Medically Responsive Epilepsy
Dr. Derek Bauer discusses optimizing management of medically responsive epilepsy. To learn more, read the article "Optimizing Management of Medically Responsive Epilepsy" by Dr. Bauer in the April 201...
23 Touko 20191min
Continuum Pearls: Important Takeaways in Evaluating Seizure Etiology
Dr. Stephan U. Schuele offers important takeaways in evaluating seizure etiology. To learn more, read the article "Evaluation of Seizure Etiology from Routine Testing to Genetic Evaluation" by Dr. Sch...
22 Touko 20192min
Long-term Outcomes of NeuroZika
Dr. Stacey Clardy discusses discusses takeaways from Dr. Annie Lannuzel's paper on the long-term outcomes of NeuroZika.
21 Touko 20191min
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors (NEJM)
Dr. Stuart Connolly discusses the main takeaways from his NEJM paper on andexanet alfa for Bleeding Associated with Factor Xa Inhibitors. Read the paper in the New England Journal of Medicine: https:/...
20 Touko 20192min
Talking to Legislators on PCORI
Dr. Jason Crowell discusses the importance of talking to legislators about PCORI. Share your story on the AAN Advocacy Action Center at https://www.aan.com/policy-and-guidelines/advocacy/aan-advocacy-...
17 Touko 20191min
Continuum Pearls: Evaluating Seizure Etiology, pt. 2
Dr. Stephan U. Schuele discusses the evaluation of seizure etiology for neurologists with more experience. To learn more, read the article "Evaluation of Seizure Etiology from Routine Testing to Genet...
16 Touko 20192min
Continuum Pearls: Evaluation of Seizure Etiology From Routine Testing to Genetic Evaluation
Dr. Stephan U. Schuele discusses the evaluation of seizure etiology. To learn more, read the article "Evaluation of Seizure Etiology from Routine Testing to Genetic Evaluation" by Dr. Schuele in the A...
15 Touko 20192min
Meta-analysis and cost-effectiveness of second-line antiepileptic drugs for status epilepticus
Dr. Ivan Sanchez Fernandez discusses the main points from his paper on meta-analysis and cost-effectiveness of second-line antiepileptic drugs for status epilepticus.
14 Touko 20192min
